320 related articles for article (PubMed ID: 12073154)
1. A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis.
Shiraishi A; Higashi S; Masaki T; Saito M; Ito M; Ikeda S; Nakamura T
Calcif Tissue Int; 2002 Jul; 71(1):69-79. PubMed ID: 12073154
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats.
Iwamoto J; Yeh JK; Schmidt A; Rowley E; Stanfield L; Takeda T; Sato M
Calcif Tissue Int; 2005 Aug; 77(2):119-26. PubMed ID: 16059775
[TBL] [Abstract][Full Text] [Related]
3. Alfacalcidol prevents age-related bone loss and causes an atypical pattern of bone formation in aged male rats.
Li M; Healy DR; Li Y; Simmons HA; Su M; Jee WS; Shen VW; Thompson DD
J Musculoskelet Neuronal Interact; 2004 Mar; 4(1):22-32. PubMed ID: 15615075
[TBL] [Abstract][Full Text] [Related]
4. Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate.
Sugimoto M; Futaki N; Harada M; Kaku S
Bone; 2013 Jan; 52(1):181-8. PubMed ID: 23041510
[TBL] [Abstract][Full Text] [Related]
5. The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.
Shiraishi A; Miyabe S; Nakano T; Umakoshi Y; Ito M; Mihara M
BMC Musculoskelet Disord; 2009 Jun; 10():66. PubMed ID: 19527501
[TBL] [Abstract][Full Text] [Related]
6. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen.
Shiraishi A; Takeda S; Masaki T; Higuchi Y; Uchiyama Y; Kubodera N; Sato K; Ikeda K; Nakamura T; Matsumoto T; Ogata E
J Bone Miner Res; 2000 Apr; 15(4):770-9. PubMed ID: 10780869
[TBL] [Abstract][Full Text] [Related]
7. [Effects of alfacalcidol on osteoporosis in ovariectomized rats].
Xia W; Meng X; Xing X
Zhonghua Yi Xue Za Zhi; 2000 Sep; 80(9):702-5. PubMed ID: 11798840
[TBL] [Abstract][Full Text] [Related]
8. Calcium supplementation does not reproduce the pharmacological efficacy of alfacalcidol for the treatment of osteoporosis in rats.
Shiraishi A; Ito M; Hayakawa N; Kubota N; Kubodera N; Ogata E
Calcif Tissue Int; 2006 Mar; 78(3):152-61. PubMed ID: 16525749
[TBL] [Abstract][Full Text] [Related]
9. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model.
Saito M; Shiraishi A; Ito M; Sakai S; Hayakawa N; Mihara M; Marumo K
Bone; 2010 Apr; 46(4):1170-9. PubMed ID: 20026440
[TBL] [Abstract][Full Text] [Related]
11. Tower climbing exercise started 3 months after ovariectomy recovers bone strength of the femur and lumbar vertebrae in aged osteopenic rats.
Notomi T; Okimoto N; Okazaki Y; Nakamura T; Suzuki M
J Bone Miner Res; 2003 Jan; 18(1):140-9. PubMed ID: 12510816
[TBL] [Abstract][Full Text] [Related]
12. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
[TBL] [Abstract][Full Text] [Related]
13. Long-term changes in bone mineral and biomechanical properties of vertebrae and femur in aging, dietary calcium restricted, and/or estrogen-deprived/-replaced rats.
Jiang Y; Zhao J; Genant HK; Dequeker J; Geusens P
J Bone Miner Res; 1997 May; 12(5):820-31. PubMed ID: 9144349
[TBL] [Abstract][Full Text] [Related]
14. Estrogen and "exercise" have a synergistic effect in preventing bone loss in the lumbar vertebra and femoral neck of the ovariectomized rat.
Li CY; Jee WS; Chen JL; Mo A; Setterberg RB; Su M; Tian XY; Ling YF; Yao W
Calcif Tissue Int; 2003 Jan; 72(1):42-9. PubMed ID: 12370795
[TBL] [Abstract][Full Text] [Related]
15. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
[TBL] [Abstract][Full Text] [Related]
16. Effects of alfacalcidol on cancellous and cortical bone mass in rats treated with glucocorticoid: a bone histomorphometry study.
Iwamoto J; Seki A; Takeda T; Yamada H; Sato Y; Yeh JK
J Nutr Sci Vitaminol (Tokyo); 2007 Jun; 53(3):191-7. PubMed ID: 17874822
[TBL] [Abstract][Full Text] [Related]
17. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.
Sampath TK; Simic P; Sendak R; Draca N; Bowe AE; O'Brien S; Schiavi SC; McPherson JM; Vukicevic S
J Bone Miner Res; 2007 Jun; 22(6):849-59. PubMed ID: 17352644
[TBL] [Abstract][Full Text] [Related]
18. A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia.
Ke HZ; Qi H; Crawford DT; Simmons HA; Xu G; Li M; Plum L; Clagett-Dame M; DeLuca HF; Thompson DD; Brown TA
J Bone Miner Res; 2005 Oct; 20(10):1742-55. PubMed ID: 16160732
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats.
Khajuria DK; Razdan R; Mahapatra DR
J Orthop Sci; 2014 Jul; 19(4):646-56. PubMed ID: 24668309
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of sodium daidzein sulfonate on trabecular bone in ovariectomized rats.
Ren P; Ji H; Shao Q; Chen X; Han J; Sun Y
Pharmacology; 2007; 79(3):129-36. PubMed ID: 17179740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
